Dr Dietmar Berger returns to big pharma

pharmafile | May 31, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atara, R&D, Sanofi, oncology, pharma, research 

Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the French firm after spending a year at US biotech Atara Biotherapeutics.

Having graduated from the University of Freiberg in 1988 Dr Berger spent the bulk of his career rising through the ranks of big pharma, taking on positions at Amgen, Bayer and Genentech.

However in May of last year, Dr Berger joined T-cell immunotherapy biotech Atara as their Global Head of R&D. Dr Berger said he chose to leave Atara in order to pursue other opportunities – analysts have suggested his move was a response to being overlooked as CEO.

With his new role at Sanofi, Dr Berger has returned to the world of big pharma in which he has forged his twenty year career.

Sanofi announced the appointment via twitter: “Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients.”

Related Content

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content